FDA Oncology Division Director Says Goal to Make Review Process “Predictable”
Three Bomb Threats At NIH In One Week result In Evacuations, Investigations
FDA Oncology Division To Develop Papers On Expectations for New Drugs
DeLap: Seven Years In industry Provided View Of Pressures On Drug Developers
With workload Up, Oncology Division To Add More Staff
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Peter F. Garrett to people with cancer: Your story has power
- What NHS-Galleri taught us—and what it didn’t
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”









